A Medical Claims Database Study of Factors Associated with Medication Adherence and Treatment Persistence in Patients Receiving PCSK9 Monoclonal Antibodies
Better adherence to oral LDL-C-lowering therapy and secondary prevention were identified as factors associated with better medication adherence and treatment persistence in patients receiving PCSK9-mAbs within the first year.
Authors
- Kazuma Iekushi (ORCID: https://orcid.org/0000-0003-1591-7578)
- Hidenori Arai (ORCID: https://orcid.org/0000-0002-9000-6849)
- Takeshi Morimoto (ORCID: https://orcid.org/0000-0002-6844-739X)
- Yuri Takahashi (ORCID: https://orcid.org/0000-0003-0649-8228)
Institutions
- Novartis (Switzerland) (CH)
- National Center for Geriatrics and Gerontology (JP)
- Hyogo University (JP)
Publication Details
- Journal
- Journal of Atherosclerosis and Thrombosis
- Published
- 2024-08-05
- DOI
- https://doi.org/10.5551/jat.64848
- Citations
- 2
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 2.26
Funders
- Novartis Pharma